Lung Cancer Panel (Mutations and Fusions -12Genes)

The Lung Cancer Panel (Mutations and Fusions - 12 Genes) is a comprehensive next-generation sequencing (NGS) based molecular test that analyses 12 clinically significant genes in lung tumour samples to detect cancer-driving mutations and gene fusions that are known to play a central role in the development and progression of lung cancer. Lung cancer remains one of the leading causes of cancer-related deaths worldwide, and a significant proportion of cases - particularly non-small cell lung cancer (NSCLC), which accounts for the majority of all lung cancer diagnoses — are driven by specific, targetable genetic alterations. This panel simultaneously examines key genes including EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, ERBB2, and others for both point mutations and gene fusions, providing a broad yet focused molecular assessment of the tumour in a single test. Identifying these genetic drivers is no longer just a diagnostic exercise - it has become the foundation of modern lung cancer treatment, where the choice of therapy is increasingly determined by the molecular profile of the tumour rather than its histological appearance alone. The Lung Cancer Panel delivers this critical information in a clinically actionable format that directly supports personalised treatment planning.

Who Should Get This Test Done?

The Lung Cancer Panel (Mutations and Fusions - 12 Genes) is recommended for individuals:

●      Have been newly diagnosed with non-small cell lung cancer (NSCLC), including lung adenocarcinoma or squamous cell carcinoma, and require molecular subtyping

●      Have advanced or metastatic lung cancer where targeted therapy or immunotherapy is being considered as a first-line or subsequent treatment option

●      Have not responded to standard platinum-based chemotherapy and require molecular guidance for alternative treatment options

●      Have experienced disease progression or relapse after initial lung cancer treatment and need reassessment of the tumour’s molecular profile

●      Are a non-smoker or light smoker diagnosed with lung cancer, as this group has a higher likelihood of harbouring actionable driver mutations such as EGFR or ALK

Why Consider This Test?

Lung cancer treatment has undergone a remarkable transformation over the past two decades, driven largely by the discovery of targetable genetic mutations and fusions that can be specifically inhibited by molecularly targeted drugs. For individuals whose tumours carry an actionable mutation - such as an EGFR sensitising mutation, ALK fusion, or ROS1 rearrangement - targeted therapy has been shown to produce significantly better response rates, longer progression-free survival, and a more favourable side effect profile compared to conventional chemotherapy. However, these therapies only work when the corresponding genetic alteration is present in the tumour, making accurate molecular testing an essential prerequisite for their use. The Lung Cancer Panel covers 12 of the most clinically relevant genes in a single comprehensive test, ensuring that no major actionable target is missed and that treatment decisions are based on the most complete molecular information available. For individuals with advanced lung cancer where time is of the essence, having all key mutations and fusions assessed simultaneously - rather than through sequential single-gene tests - means that the right treatment can be identified and initiated without unnecessary delay. This panel can genuinely change the treatment trajectory for lung cancer patients and, in many cases, significantly improve their outcomes and quality of life.

More Information

Using next-generation sequencing (NGS), the panel simultaneously detects mutations, insertions/deletions, copy number variations, and gene fusions across 12 clinically relevant lung cancer genes. Results are usually available within 1-2 weeks (Terms and conditions apply) and are reported with the detected genetic alterations, their clinical significance, and potential targeted therapy options. Results should be interpreted by the treating oncologist in the context of the individual’s clinical history, disease stage, and treatment guidelines. Since tumour genetics can change over time, especially after targeted therapy, repeat testing at disease progression may be necessary to identify resistance mechanisms and guide further treatment.

Other Names

●      Lung Cancer Molecular Panel

●      NSCLC Mutation and Fusion Panel

●      Lung Tumour NGS Panel

●      Lung Cancer Targeted Gene Panel

●      Non-Small Cell Lung Cancer Molecular Profiling Test

●      Lung Cancer Driver Mutation Panel

●      Lung Cancer Gene Fusion and Mutation Test

●      Pulmonary Carcinoma Molecular Panel

●      Lung Cancer Actionable Mutation Panel